Healthcare Reform
Medicaid 2014: Planning Your Strategy
As you look over the Medicaid landscape for next year, there is more than a little uncertainty at hand. With Medicaid about to become the basic health care delivery mechanism of the 2010 Affordable Care Act, you would think this might be a simple matter of reviewing the new federal law for guidance. But if that’s the approach you are taking for your 2014 Medicaid planning, you’re going down the wrong path, says Tom Norton ...Read more
CEO Compensation Data
Complete salary, bonus & market capitalization data in biotech.
 www.bioworld.com
Regulatory
Xofigo keeps the Approval Ball rolling for Bayer
US-based Bayer Healthcare Pharmaceuticals has now received three new approvals for cancer indications in the last eight months. Two were for Stivarga, for metastatic colorectal cancer at the end of last September, and for gastrointestinal stromal tumor, or GIST, in February. And on Wednesday, FDA approved Xofigo (radium Ra 223 dichloride), an alpha-emitting radioactive drug indicated for symptomatic late-stage metastatic castration-resistant prostate cancer ...Read More
The Waiting Game: Ways to Prepare for the AMP Final Rule
Live Webcast: Tuesday, June 4, 2013 from Noon to 1:00 PM Eastern
Register Free at
www.pharmexec.com/ampfinal
Social Media & Marketing
Could Pharma Do Tumblr?
Tumblr, which has just been bought by Yahoo for $1.1 billion, is cool, nimble, and on the up. So it’s not difficult to understand why you’ll find very few, if any, pharma company on the blogging platform. But it might be time to make Tumblr part of your marketing plan, writes Peter Houston ...Read more
Social Media & Marketing
Protect Your “Online Reputation”
For CEOs who have spent long years and countless funds building a solid pharmaceutical brand and life-changing drugs, discovering defamatory remarks about your company online can come as quite a shock. And because they rank so high, these complaints often show up in search results years after the problem is resolved, diminishing your reputation both immediately and over the long-term. Should what should you do about it? ...Read more
Global
Read the New Pharm Exec Global Digest — Patents Special
In May’s issue: India’s Glivec Ruling — the Aftermath; Europe’s Unitary Patent — cause for excitement?; the UK Patent Box — will it hold delights for the industry? Also: a new era for UK’s NICE; smarter multichannel marketing; and more ...Read more
|
